PANORAMA 2 Observational Study

Completed

• Conditions: Heart Rhythm Disorders

• Registration Number: NCT01723566
• Lead Sponsor: Medtronic Bakken Research Center

Brief Summary

Understanding the clinical practice of treatment of cardiac rhythm disorders all over the world and understanding the clinical outcomes of the treatment with its cardiac rhythm products in real world patient population is essential for Medtronic to be able to effectively develop new products and adjust existing products. In addition Medtronic is committed to monitor the safety of its products throughout the entire life cycle to ensure maximum product reliability.

The Panorama 2 registry will enable Medtronic to increase data collection of clinical practice with Medtronic implantable Cardiac Rhythm and Disease Management (CRDM) devices in various regions across the world and on product reliability of its CRDM devices.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-07-25
• Study First Submitted: 2012-11-06
• Study First Submitted QC: 2012-11-06
• Study First Posted: 2012-11-08
• Primary Completion: 2016-10-31
• Study Completion: 2016-10-31
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-31
• Last Update Posted: 2017-09-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4706

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Describe region-specific clinical practice of CRDM device use	2012-2019	To describe the region-specific current clinical practices associated with the device treatment of patients receiving implantable Medtronic CRDM devices by collecting information on the patient characteristics (demographics, medical history and cardiovascular status), the type of Medtronic CRDM devices used, the indication for the use of the Medtronic CRDM devices and the clinical outcomes of the treatment with the Medtronic CRDM devices (all deaths, cardiovascular hospitalizations, Serious Adverse Device Effects and NYHA class).

Trial Locations

Locations (1)

Cairo University Hospital; 🇪🇬 Cairo, Egypt